Today: 30 June 2026
Browse Category

NYSE:GE 5 February 2026 - 28 February 2026

GE Aerospace stock price jumps on Morgan Stanley’s $425 call — what to watch before Monday

GE Aerospace stock price jumps on Morgan Stanley’s $425 call — what to watch before Monday

New York, February 22, 2026, 14:25 — The market has closed. Shares of GE Aerospace climbed 2.5% Friday, closing at $343.22, following Morgan Stanley’s launch of coverage with an Overweight rating and a $425 target. Analysts at the firm described the jet-engine manufacturer as “best in class” and highlighted its “deep competitive moat.” U.S. markets remain closed on Sunday.
GE Vernova stock slips from recent highs after 2030 turbine slot deal — what GEV investors watch next

GE Vernova stock slips from recent highs after 2030 turbine slot deal — what GEV investors watch next

New York, Feb 10, 2026, 11:35 EST — Regular session trading underway. GE Vernova lost ground Tuesday, slipping 0.7% to $796.29 by late session. Monday’s close was $801.54. The stock’s range: $787.91 on the low end, up to $809.01. It kicked off the day at $803.00, with investors mulling fresh signs of customers locking in sizable gas turbine orders years ahead.
Defense and space stocks rally, but Trump’s buyback-dividend squeeze is the next test

Defense and space stocks rally, but Trump’s buyback-dividend squeeze is the next test

New York, Feb 7, 2026, 12:51 EST — Market closed. Space and defense names trading in the U.S. finished in the green Friday. The market’s focus, though, has shifted—earnings aren’t the spark this time, nor is fresh demand for missiles. Instead, investors are eyeing an upcoming Pentagon list that threatens to restrict buybacks and dividends for contractors failing to meet delivery targets.
1 2 3 4 9

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Go toTop